AAV Capsid Engineering for CNS-Targeted Neurodegeneration Therapy

AAV Capsid Engineering for CNS-Targeted Neurodegeneration Therapy

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
• Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
• Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
• Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72

AAV Capsid Engineering for CNS-Targeted Neurodegeneration Therapy

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
• Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
• Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
• Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HTT](/genes/htt)
• Mechanisms: [[neuroinflammation](/mechanisms/neuroinflammation)](/mechanisms/[neuroinflammation](/mechanisms/neuroinflammation)), [[mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)](/mechanisms/mitochondrial-dysfunction), [[lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)](/mechanisms/lysosomal-dysfunction), [[protein aggregation](/mechanisms/protein-aggregation)](/mechanisms/protein-aggregation), [[oxidative stress](/mechanisms/oxidative-stress)](/mechanisms/oxidative-stress), [[autophagy](/mechanisms/autophagy)](/mechanisms/[autophagy](/mechanisms/autophagy)), [[synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction](/mechanisms/[synaptic dysfunction](/mechanisms/synaptic-dysfunction)-dysfunction)
• Therapeutics: [[gene therapy](/therapeutics/gene-therapy-neurodegeneration)](/therapeutics/gene-therapy-neurodegeneration), [ASOs](/therapeutics/antisense-oligonucleotides), [CRISPR gene editing](/therapeutics/crispr-gene-editing-neurodegeneration), [deep brain stimulation](/therapeutics/deep-brain-stimulation)
• Pathways: [complement system](/mechanisms/complement-system-pathway), [neurotrophic signaling](/mechanisms/neurotrophic-factor-signaling), [cell death pathways](/mechanisms/cell-death-pathways-neurodegeneration)

Overview

This therapeutic concept leverages advances in AAV capsid engineering to achieve enhanced brain delivery for [gene therapy](/therapeutics/gene-therapy-neurodegeneration) approaches targeting neurodegenerative diseases. While traditional AAV serotypes (AAV2, AAV9, AAVrh.10) provide some CNS transduction, engineering novel capsids can dramatically improve [blood-brain barrier](/entities/blood-brain-barrier) (BBB) crossing, cell-type specificity, and reduce immunogenicity—addressing the primary bottleneck in CNS [gene therapy](/therapeutics/gene-therapy-neurodegeneration).

Target Rationale

The Delivery Challenge

The [blood-brain barrier](/entities/blood-brain-barrier) remains the primary obstacle for CNS [gene therapy](/therapeutics/gene-therapy-neurodegeneration). Standard AAV serotypes require high doses for meaningful brain transduction, increasing manufacturing costs and immunogenicity risks. Engineered capsids offer a solution by:

Neurodegeneration-Specific Needs

Different neurodegenerative diseases require distinct cell-type targeting:

• [Alzheimer's disease](/diseases/alzheimers-disease) — Need for astrocyte and [microglia](/cell-types/microglia)l targeting to address amyloid clearance and [neuroinflammation](/mechanisms/neuroinflammation)
• [Parkinson's disease](/diseases/parkinsons-disease) — Dopaminergic neuron targeting essential for SNCA silencing, GBA enhancement
• [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia) — Motor neuron and glial targeting ([astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia)) for SOD1, C9orf72, TDP-43
• [Huntington's disease](/diseases/huntingtons-disease) — Striatal neuron targeting for HTT gene silencing

Mechanism of Action

Capsid Engineering Approaches

Key Engineered Capsids

| Capsid | Properties | Relevance |
|--------|------------|-----------|
| AAV-PHP.B | Enhanced CNS transduction via unknown mechanism | Broad neurodegeneration |
| AAV-PHP.EB | Even higher CNS transduction, reduced peripheral toxicity | Pre-clinical |
| AAV-CAP-NN | Machine learning-designed, BBB-crossing | Development |
| AAV-9 null | Reduced liver tropism, enhanced CNS | Clinical |

Therapeutic Strategy

Combination with RNA-Targeting Payloads

Engineered capsids can be combined with RNA-targeting payloads:

• ASO delivery — Direct brain injection with engineered AAV capsids for sustained ASO expression
• RNAi/SiRNA — AAV-delivered shRNA for knockdown of disease-driving genes (SNCA, HTT, SOD1)
• CRISPR components — AAV-mediated base editing or prime editing for precise genetic correction

Dosing Considerations

• Systemic delivery — IV administration with engineered capsids at 1×10^14 vg/kg
• Intrathecal delivery — For direct CNS delivery with lower systemic exposure
• Combination approaches — Initial systemic dose followed by targeted intrathecal boosters

10-Dimension Rubric Scoring

Novelty (8/10)

• AAV capsid engineering is established but combining with neurodegeneration-specific targeting is novel
• New machine learning approaches enable rapid capsid optimization

Mechanistic Rationale (9/10)

• Strong biological basis: receptor-mediated transcytosis is well-characterized
• Direct evolution has identified capsids with 10-100x enhanced brain transduction

Root-Cause Coverage (7/10)

• Addresses delivery bottleneck, not disease mechanism itself
• Can be combined with any genetic or RNA-targeting payload

Delivery Feasibility (8/10)

• Manufacturing processes established for AAV at scale
• Clinical-grade capsid engineering feasible

Safety Plausibility (8/10)

• Lower dosing reduces immunogenicity risk
• Cell-type specificity improves safety profile

Combinability (9/10)

• Platform technology compatible with all [gene therapy](/therapeutics/gene-therapy-neurodegeneration) payloads
• Synergistic with RNA-targeting, CRISPR, and small molecule approaches

Biomarker Availability (7/10)

• Vector genome copy number in CSF as pharmacodynamic marker
• Reporter gene expression in patient-derived cells

De-risking Path (8/10)

• Clear path: capsid optimization in non-human primates → IND-enabling studies → clinical
• Regulatory precedent: AAV gene therapies approved for CNS (onasemnogene)

Multi-disease Potential (10/10)

• Universal platform for AD, PD, ALS, FTD, HD, and other CNS diseases
• Addresses delivery across entire neurodegeneration pipeline

Patient Impact (8/10)

• Improved delivery could unlock [gene therapy](/therapeutics/gene-therapy-neurodegeneration) for previously inaccessible diseases
• Reduced dosing improves safety and access

Disease Coverage Matrix

| Disease | Coverage Score | Rationale |
|---------|---------------|-----------|
| Alzheimer's Disease | 8 | Astrocyte/[microglia](/cell-types/microglia)l targeting for amyloid clearance |
| Parkinson's Disease | 9 | Dopaminergic neuron targeting for SNCA, GBA |
| [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia) | 9 | Motor neuron and glial targeting |
| Frontotemporal Dementia | 8 | Frontal cortex targeting |
| Huntington's Disease | 9 | Striatal neuron targeting |
| PSP | 7 | Brainstem targeting |
| MSA | 6 | Mixed cell type targeting |
| Aging | 8 | Platform applicable to age-related diseases |

Implementation Roadmap

Phase 1: Preclinical (Years 1-2)

Phase 2: IND-Enabling (Years 2-3)

Phase 3: Clinical (Years 3-5)

De-risking Considerations

Technical Risks

• Immunogenicity — Engineered capsids may still generate immune response; mitigate with steroid pre-treatment and immunosuppression
• Manufacturing — Engineered capsids may have reduced packaging efficiency; optimize production in stable cell lines
• Specificity — May not achieve desired cell-type specificity; develop dual-targeting approaches

Regulatory Pathway

• Clear regulatory precedent with AAV gene therapies
• Breakthrough Therapy designation possible based on unmet need
• Accelerated approval pathway for life-threatening indications

Actionable Next Steps

References